Reply to Harrington et al.

Clin Infect Dis

Institute of Human Virology, University of Maryland, Baltimore Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.

Published: August 2015

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4542601PMC
http://dx.doi.org/10.1093/cid/civ403DOI Listing

Publication Analysis

Top Keywords

reply harrington
4
reply
1

Similar Publications

Reply to letter regarding "Sirolimus-coated balloon versus drug-eluting stent for complex coronary lesions: A propensity matched comparison".

Int J Cardiol

January 2025

DCB Academy, Milano, Italy; Fondazione Ricerca e Innovazione Cardiovascolare, Milano, Italy; Harrington Heart & Vascular Institute, University Hospitals Cleveland Medical Center, Cleveland, OH, USA. Electronic address:

View Article and Find Full Text PDF

The Reply.

Am J Med

July 2024

Department of Medicine/Cardiology, Icahn School of Medicine at Mount Sinai, The Zena and Michael A. Wiener Cardiovascular Institute and the Marie-Josée Henry R. Kravis Cardiovascular Health Center, Icahn School of Medicine at the Mount Sinai Hospital, Mount Sinai Heart, New York, NY.

View Article and Find Full Text PDF

Background: The initiation of clinical trials for messenger RNA (mRNA) HIV vaccines in early 2022 revived public discussion on HIV vaccines after 3 decades of unsuccessful research. These trials followed the success of mRNA technology in COVID-19 vaccines but unfolded amid intense vaccine debates during the COVID-19 pandemic. It is crucial to gain insights into public discourse and reactions about potential new vaccines, and social media platforms such as X (formerly known as Twitter) provide important channels.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!